Thrombin-antithrombin (TAT) complexes in pulmonary hypertension

P. Jansa, M. Sidova, H. Spundova, Z. Susa, M. Aschermann (Prague, Czech Republic)

Source: Annual Congress 2003 - Pulmonary hypertension
Session: Pulmonary hypertension
Session type: Thematic Poster Session
Number: 2928
Disease area: Interstitial lung diseases, Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Jansa, M. Sidova, H. Spundova, Z. Susa, M. Aschermann (Prague, Czech Republic). Thrombin-antithrombin (TAT) complexes in pulmonary hypertension. Eur Respir J 2003; 22: Suppl. 45, 2928

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Prognoctic value of platelet factor-4 and thrombin-antithrombin complex for pulmonary hypertension among patients with idiopathic interstitial pneumonias
Source: Eur Respir J 2006; 28: Suppl. 50, 658s
Year: 2006

Platelets and pulmonary arterial hypertension (PAH)
Source: International Congress 2019 – Pulmonary hypertension: clinical
Year: 2019

Chronic thromboembolic pulmonary hypertension (CTEPH) and coagulation defects: Before and after treatment
Source: International Congress 2017 – PAH and CTEPH
Year: 2017


Association between alpha1 antitrypsin (AAT) circulating polymers (CP) and lung and liver disease in patients with AAT deficiency (AATD).
Source: Virtual Congress 2021 – Molecular pathology and cell biology of pulmonary diseases
Year: 2021


D-dimer in diagnosis of pulmonary embolization (PE)
Source: Eur Respir J 2006; 28: Suppl. 50, 46s
Year: 2006

Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015


Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008


Pulmonary hypertension (PH) associated with haemolysis
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008

Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010


Fibrinogen Aα Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2008; 31: 736-741
Year: 2008



Epoprostenol (EPT) for acute reactivity testing (AVT) in pulmonary artery hypertension (PAH)
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004

Liver function in patients with pulmonary tuberculosis (PT) before and during the initial phase of antituberculosis treatment (ATT)
Source: Eur Respir J 2002; 20: Suppl. 38, 365s
Year: 2002

Platelet-activating factor-acetylhydrolase (PAF-AH) activity in pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2005; 26: Suppl. 49, 695s
Year: 2005

Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008

Arterial hypertension (AH) and endothelial function (EF) in patients with COPD
Source: Annual Congress 2011 - COPD mechanisms
Year: 2011

Effect of serum alpha-1-antitrypsin (AAT) and alpha-2-macroglobulin (AMG) levels on sputum conversion in active pulmonary tuberculosis
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008


Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 354s
Year: 2006

The right ventricle (RV) in systemic sclerosis-associated pulmonary arterial hypertension (SSCPH) vs idiopathic pulmonary arterial hypertension (IPH): higher inflammatory status, no increase in interstitial fibrosis
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009

Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH)
Source: Eur Respir J 2003; 22: Suppl. 45, 270s
Year: 2003

6MWD in patients with pulmonary arterial hypertension (PAH)
Source: Eur Respir J 2003; 22: Suppl. 45, 464s
Year: 2003